معرفی
Dr. Gareth Owain Richards is a Senior Research Fellow at the School of Medicine and Population Health, University of Sheffield, where he also serves as the I&KE Lead for Seed Innovation, IP, and Commercialisation. He is based in the Department of Oncology and Metabolism and leads a dynamic research group focused on GPCR/RAMP interactions with applications in cancer, endocrinology, and bone biology.
- PhD in Molecular Pharmacology, University of Sheffield
- Senior Research Fellow, Department of Oncology and Metabolism
- I&KE Lead for Seed Innovation, IP, and Commercialisation
- Member, Healthy Lifespan Institute (HELSI) Executive Board
- Workstream Lead for Drug Discovery, HELSI
His research centers on the molecular pharmacology of G protein-coupled receptors (GPCRs) and their interactions with receptor activity-modifying proteins (RAMPs), particularly in the context of endocrinology, cancer, and bone biology. He investigates how RAMPs modulate receptor signaling and how these insights can be translated into novel therapeutics, including small molecules and antibodies for conditions like pancreatic cancer and septic shock.
Dr. Richards has a strong entrepreneurial profile, having co-founded two spin-out companies: Medella Therapeutics and Modulus Oncology. His recent publications reflect a consistent focus on RAMP-GPCR complexes, bone metabolism, cancer signaling, and drug discovery. The work spans from fundamental molecular mechanisms to translational applications, with a growing emphasis on high-throughput screening and therapeutic development.
Scientific awards and recognitions include:
- Fellow of the Higher Education Academy (SFHEA)
He actively supervises multiple PhD students and holds significant research grants from MRC, Wellcome Trust, and Prostate Cancer UK. He collaborates with Prof Tim Skerry, Prof Joe Harrity, and Dr Tim Craggs, fostering interdisciplinary research. Dr. Richards also contributes to teaching as the module lead for MED6098 in the MSc in Molecular Medicine and Drug Discovery programs, emphasizing practical skills and innovation.
His research group includes postdoctoral researchers, PhD students, and technical staff, working on projects such as RAMP-PTH1R interactions, GPER modulation in breast cancer, and AM2R antagonists for leukemia and septic shock. He is deeply involved in promoting innovation culture within the medical school, supporting technology transfer and commercialisation of academic research.
